Data sets up ulcerative colitis expansion for BMS’ MS drug ZeposiaBristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – Share XData sets up ulcerative colitis expansion for BMS’ MS drug Zeposiahttps://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/
Despite biosims, ulcerative colitis drugs still cost too much; ICERNone of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough Share XDespite biosims, ulcerative colitis drugs still cost too much; ICERhttps://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/
Takeda posts surprise profit a year after Shire mega-mergerJapan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year Share XTakeda posts surprise profit a year after Shire mega-mergerhttps://pharmaphorum.com/news/takeda-posts-surprise-profit-a-year-after-shire-mega-merger/
Ferring’s gut microbiome drug clears phase 3 trial in C. diffFerring Pharma has reported what it says is the first positive phase 3 trial of a microbiome therapy Share XFerring’s gut microbiome drug clears phase 3 trial in C. diffhttps://pharmaphorum.com/news/ferrings-gut-microbiome-drug-clears-phase-3-trial-in-c-diff/
FDA says all ranitidine drugs should be recalled on safety concernsThe FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market Share XFDA says all ranitidine drugs should be recalled on safety concernshttps://pharmaphorum.com/news/fda-says-all-ranitidine-drugs-should-be-recalled-on-safety-concerns/
Takeda buys US biotech PvP Biologics for $330 millionTakeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for Share XTakeda buys US biotech PvP Biologics for $330 millionhttps://pharmaphorum.com/news/takeda-buys-us-biotech-pvp-biologics-for-330-million/
Takeda buys coeliac drug licence from COUR PharmaceuticalsTakeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced Share XTakeda buys coeliac drug licence from COUR Pharmaceuticalshttps://pharmaphorum.com/news/takeda-buys-coeliac-drug-licence-from-cour-pharmaceuticals/
AZ sells rights to gastro drug Losec to Cheplapharm in $309m dealAstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands Share XAZ sells rights to gastro drug Losec to Cheplapharm in $309m dealhttps://pharmaphorum.com/news/az-sells-rights-to-gastro-drug-losec-to-cheplapharm/
Multiple pharmas pull ranitidine stomach drugs amid growing cancer scareSupplies of the heartburn drug ranitidine have been recalled globally following a cancer scare involving multiple pharma companies, Share XMultiple pharmas pull ranitidine stomach drugs amid growing cancer scarehttps://pharmaphorum.com/news/multiple-pharmas-pull-ranitidine-stomach-drugs-amid-growing-cancer-scare/
